Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...

The study also included an 18-week open-label phase, during which patients with Schizophrenia were treated with Lumateperone 42 mg per day. The biopharmaceutical company found that the time to relapse ...

While the suburb is close enough to the action in the centre of Coventry, it’s far away enough that you can retreat into peaceful suburban solitude. The survey praised the eating options and the ...

Part of a Coventry supermarket will be turned into flats. Council officers approved the scheme at Nisa Extra in Allesley Park last week, 25 October. It comes after a decline in customers to the store.

The Coventry Police Department said a dog owner requested that their dog be killed because it had an aggressive temperament. It happened on Oct. 24. Investigators arrested Anthony Demitraszek as a ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new, positive data on social ...

said long-term therapy with Cobenfy improved schizophrenia symptoms across all efficacy measures. While there were no new safety or tolerability issues, discontinuation rates due to treatment ...

Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...

This image provided by Bristol Myers Squibb in October 2024 shows the company's drug Cobenfy, which the U.S. Food and Drug Administration approved for the treatment of schizophrenia in September 2024.